Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is an autoimmune disease where the body's immune system mistakenly attacks healthy tissue, leading to inflammation and damage in various organs.
We are testing a new therapy using engineered immune cells for people with active B-cell driven autoimmune diseases. The study aims to assess safety and effectiveness in conditions like lupus and scleroderma.
Health conditions and diseases that the clinical trial is designed to study and treat.
Systemic Lupus Erythematosus (SLE) is an autoimmune disease where the body's immune system mistakenly attacks healthy tissue, leading to inflammation and damage in various organs.
Systemic Sclerosis (Scleroderma) is a rare autoimmune disease that causes the skin and connective tissues to harden and tighten, potentially affecting internal organs.
Idiopathic Inflammatory Myopathy is a group of diseases characterized by muscle inflammation and weakness, often affecting the ability to perform daily activities.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.